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Edited by Barry HalliwellAbstract Dehydroartemisinin (DHA) is an eﬀective anti-malar-
ia agent. Fortilin is an anti-apoptotic molecule overexpressed in
many human cancers. Here, we show that DHA binds human
fortilin, increases the ubiquitination of fortilin, shortens fortilins
half-life in a proteasome-dependent fashion, and reduces cellular
levels of fortilin in varieties of cells. DHA induced DNA frag-
mentation in U2OS cells in a fortilin-dependent manner. The
fortilin-knocked-down cells were less susceptible—and fortilin-
overexpressing cells more susceptible—to DHA than were
wild-type cells, suggesting that apoptotic eﬀects of DHA are—
at least partly—conferred through fortilin. Together, these data
suggest that fortilin is a molecular target of DHA. DHA and its
derivative may prove to be viable anti-cancer agents in fortilin-
overexpressing cancers.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Fortilin, also known as translationally controlled tumor pro-
tein (TCTP) and histamine releasing factor (HRP), possess po-
tent anti-apoptotic function [1]. In human cells, fortilin
overexpression protects cells against apoptosis induced by che-
motherapeutic agents such as etoposide [1] and 5-ﬂuorouracil
(5-FU) [2] while fortilin depletion either precipitates spontane-
ous apoptosis or increases sensitivity to cytotoxic stimuli [1,3].
Importantly, the expression of human fortilin is far greater in
cancerous cells and tissue than their normal counterparts [3].
Although these observations suggest that human fortilin inhib-
itors are viable anti-cancer agents, there has been no such com-
pound reported.Abbreviations: DHA, dihydroartemisinin; TCTP, translationally con-
trolled tumor protein; HRP, histamine releasing factor; ANOVA,
analysis of variance; SPR, surface plasmon resonance
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doi:10.1016/j.febslet.2008.02.055Dehydroartemisinin (DHA, Fig. 1B) is a metabolite of arte-
misinin—an active ingredient of sweet wormwood Artemisia
annua (Qing Hao) (Fig. 1A) [4,5]. Both artemisinin and DHA
are highly eﬀective anti-malaria agents and are well tolerated
[6–8]. Bhisutthibhan and others reported that DHA binds ma-
laria fortilin in vivo [9–11]. Based on the fact that fortilin is
highly conserved across species—human (GenBank accession
number: NP_003286) and malaria (GenBank accession num-
ber AAZ73158) fortilins shares 33% and 58% of identity and
homology, respectively, we hypothesized that DHA also binds
and inhibits human fortilin.
Here, we report that the DHA binds human fortilin at the
dissociation constant (Kd) of 38 lM as assessed by the surface
plasmon resonance-based methods. We further report that the
binding of DHA to human fortilin results in the shortening of
the half-life of fortilin, via the ubiquitination of fortilin and
subsequent proteaseome-mediated degradation.
We demonstrate that DHA reduces cellular fortilin levels in
many human cell lines despite the transcriptional activation of
fortilin gene. We establish that fortilin is required for the full
apoptotic eﬀects of DHA in U2OS cells. We propose that
DHA is a novel human fortilin inhibitor.2. Materials and methods
2.1. Generation of recombinant proteins
Recombinant GST-human fortilin and GST-alone were produced as
previously described [12]. Detailed description on Materials and Meth-
ods can be found in Supplementary materials.
2.2. Generation of U2OS stable transfectants
U2OS cells stably overexpressing fortilin (U2OS-fortilin) or harbor-
ing empty plasmid (U2OS-empty) were generated as described previ-
ously by us [2]. U2OS-sh-fortilin, U2OS cells that stably harbor a
short-hairpin RNA against fortilin (shRNA-fortilin) and express much
lower levels of fortilin, were generated as described in detail within
Supplementary materials.
2.3. Measurement of surface plasmon resonance (SPR)
All analyses were carried out using a Biacore T100 (Biacore Inc.,
Part of GE Healthcare, Piscataway, NJ) as described previously
[13,14]. GST-human-fortilin (will be called GST-fortilin hereafter) or
GST alone were directly coupled to a Series S CM5 chip. For binding
assays, the ﬂow rate of running buﬀer—HBS-EP+ (10 mMHEPES, pH
7.4, 150 mM NaCl, 3 mM EDTA, and 0.05% v/v surfactant P20)—was
maintained at 30 lL/min at 25 C. For each sample cycle, DHA at the
concentrations between 0 and 100 lMwere injected for a period of 30 s
followed by an un-disturbed dissociation period of 10 s. Sensorgrams
for various concentrations of DHA were obtained and subjected to
steady-state aﬃnity analysis [13,14]. Data were double reference sub-
tracted and solvent (DMSO) corrected.blished by Elsevier B.V. All rights reserved.
Fig. 1. Chemical structure of artemisinin and dihydroartemisinin
(DHA). (A) Artemisinin (C15H22O5, Molecular weight [MW] = 282.33)
is a sesquiterpene with endoperoxides (a peroxy group). (B) Dihyd-
roartemisinin (DHA, C15H24O5, MW = 284.35) is a metabolite of
artemisinin.
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Western blot analyses—using anti-fortilin and anti-GAPDH anti-
bodies—and quantitative signal analyses were performed as previously
described by us [1,15].
2.5. Half-life analysis of fortilin
U2OS cells (1 · 105) were seeded in wells of 6-well dishes, pre-treated
with 30 mg/mL cyclohexamide (Sigma), treated with 20 lMDHA, har-
vested into SDS loading buﬀer at times 0, 1,3, 5, and 8 h. When appro-
priate, cells were also treated by 10 lM MG-132, a proteasome
inhibitor (Sigma). Samples were then subjected to Western blot analy-
ses as described above. For the determination of steady-state level of
fortilin, cells (1 · 105) were seeded in wells of 6-well dishes, treated with
vehicle alone (DMSO), 20 lM and 50 lMDHA for 48 h and harvested
into SDS loading buﬀer. Experiments were repeated twice with the
same results.
2.6. Real-time quantitative PCR (qRT-PCR) of fortilin
The qRT-PCR of fortilin was performed as previously described by
us [15].
2.7. Fortilin ubiquitination assay
U2OS cells were co-transfected with pcDNA3-Ubiquitin (pcDNA-
Ub) and pFLAG-fortilin, and treated with 0, 25, and 50 lM DHA
for 24 h. Extracted proteins were subjected to Western blot analyses
using anti-FLAG (M2, Sigma) and anti-GAPDH (Fitzgerald Indus-
tries Inc.) antibodies.
2.8. DNA fragmentation assay
U2OS-fortilin, U2OS-empty, U2OS-sh-fortilin, and U2OS-sh-empty
(0.2 · 104 per well) were seeded into 24-well plates, challenged by 20 lM
DHA or vehicle (DMSO), incubated for 48 h, and subjected to a DNA
fragmentation assay using the Cell Death Detection ELISAPLUS kit
(Roche). After the assay, cells were subjected to SDS–PAGE and Wes-
tern blot analysis using anti-fortilin and anti-GAPDH antibodies.
2.9. Statistical analyses
All data were expressed as the means ± standard deviation (S.D.). A
P value of less than 0.05 was considered to be statistically signiﬁcant.3. Results
3.1. DHA binds human fortilin
In order to determine whether DHA (Fig. 1B) binds human
fortilin, we performed SPR experiments. Representative sen-
sorgrams obtained for GST-fortilin and GST alone are shown
in Fig. 2A and C, respectively. The binding of DHA to GST-
fortilin occurred rapidly before achieving a steady-state bind-ing level during the sample injection. Subsequently, a fast dis-
sociation phase—almost instantaneous at the end of DHA
injection—was observed. The equilibrium dissociation con-
stant of DHA binding to fortilin was calculated at 38 lM
(Fig. 2B), using the steady-state aﬃnity analysis model
[13,14]. There was no signiﬁcant binding of DHA to GST
alone observed (Fig. 2C).
3.2. DHA shortens the half-life of fortilin
We then treated U2OS cells with cyclohexamide and then
with DHA and subjected cells to Western blot analyses at 0,
1, 3, 5, and 8 h. In the absence of DHA, the intracellular levels
of fortilin gradually decreased over an 8 h period (Vehicle,
Fig. 3A and DHA [], Fig. 3B), with the extrapolated half-life
of 11.6 h. In this system, the presence of DHA was associated
with much faster decrease in fortilin levels (fortilin expression
indices at 8 h = 56.9 vs. 30.8% for DHA [] and DHA [+],
respectively, Fig. 3B), with the estimated half-life of 6.3 h. Ta-
ken together with the fact that DHA speciﬁcally binds fortilin
(Fig. 2A and B), these data suggest that the binding of DHA to
fortilin facilitates the degradation of fortilin in vivo.3.3. DHA-induced shortening of fortilins half-life is mediated by
ubiquitin-proteasome pathway
Next, we repeated the same experiment described above, in
the presence of MG132, a potent inhibitor of the proteasome
pathway [16]. In the absence of DHA, fortilin signal slowly de-
creased over time, with fortilin expression index reaching at
74.7% of time zero by 8 h (top panel, Fig. 4A and DHA
[][open circles], Fig. 4B). In the presence of 20 lMDHA, for-
tilin signals decreased more rapidly, with fortilin expression in-
dex reaching at 51.6% of time zero at 8 h (middle panel,
Fig. 4A and DHA[+][closed circles], Fig. 4B). In this system,
the addition of MG132 increased fortilin levels in all time
points, with essentially no reduction of fortilin levels over 8 h
(98.3% at 8 h, bottom panel, Fig. 4A and DHA+MG132
[closed triangles], Fig. 4B).
Next, we performed fortilin ubiquitination assays where
U2OS cells were co-transfected with pcDNA-Ub and
pFLAG-fortilin plasmid vectors, divided into three dishes,
and treated by 0, 25, and 50 lM DHA for 24 h. The cells were
harvested and extracted proteins were subjected toWestern blot
analyses, using anti-FLAG and anti-GAPDH antibodies. As is
shown in Fig. 5, DHA dose-dependently increased the ubiquiti-
nation of fortilin. Taken together with the data presented in
Fig. 4, these ﬁndings suggest that ubiquitin-proteasome path-
ways contribute to the degradation of DHA-bound fortilin.3.4. DHA decreases the steady-state levels of fortilin in U2OS
cells
Next, we treated U2OS cells for 48 h with DHA in the ab-
sence of cyclohexamide. Western blot analyses showed that
fortilin levels dose-dependently decreased with chronic DHA
treatment, even in the absence of cyclohexamide (fortilin
expression index = 100 ± 4.2, 55.3 ± 0.7, 25.1 ± 10.5%, for 0,
20, and 50 lM DHA, respectively, P = 0.003 by one-way anal-
ysis of variance (ANOVA), Fig. 6A and B). These data suggest
that a long-term treatment of cells with DHA is associated
with reduced levels of intracellular fortilin levels and that
DHA can be utilized to reduce the levels of intracellular forti-
lin in vivo, without protein synthesis inhibitors.
Fig. 2. DHA binds human fortilin as detected by the surface plasmon resonance (SPR) measurement. GST-fortilin, GST-fused to the N-terminus of
human fortilin; GST, GST-only protein; RU, resonance units; Kd, equilibrium dissociation constant. (A) Sensorgrams of DHA binding to human
fortilin. (B) Calculation of Kd by the steady-state aﬃnity analysis model. (C) Sensorgrams showing the lack of interaction between DHA and GST.
All analyses were carried out using a Biacore T100 (Biacore Inc., Part of GE Healthcare, Piscataway, NJ) as described in the Materials and Methods
section. GST-fortilin (A, B) or GST alone (C) was immobilized to the carboxymethylated (CM) sensor surface of a Series S CM5 chip. DHA at the
concentrations between 0 and 100 lM were injected for a period of 30 s followed by an un-disturbed dissociation period of 10 s. Sensorgrams for
various concentrations of DHA were obtained. Data were double reference subtracted and solvent (DMSO) corrected.
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associated with increase in fortilin messages
Next, we quantiﬁed fortilin message levels of U2OS cells that
had been treated with vehicle, 20, 35, and 50 lMDHA for 48 h
in the absence of cyclohexamide. As is shown in Fig. 6C, for-
tilin message increased signiﬁcantly as cells were treated with
increasingly high concentrations of DHA (fortilin message in-
dex [fg of fortilin mRNA per 1 ng of total RNA loaded] =
3.93 ± 0.47, 3.97 ± 0.21, 4.86 ± 0.40, and 5.12 ± 0.60, for 0,
20, 35, and 50 lM DHA, respectively, P = 0.02 by one-way
ANOVA). These data suggest that the long-term administra-
tion of DHA, despite the transcriptional activation of fortilingene (Fig. 6C), reduces the intracellular levels (Fig. 6A and
B) of fortilin protein through the shortening of fortilins half-
life (Fig. 3) via the activation of the ubiquitin-proteasome
pathway (Figs. 4 and 5).
3.6. DHA reduces intracellular fortilin levels in many cell types
We then treated various cell lines with 20 lM of DHA for
48 h, in the absence of cyclohexamide, and subjected them to
Western blot analyses. As is shown in Fig. 7, DHA substan-
tively reduced cellular fortilin levels in VSMC, A549, H1299,
U2OS, MDA468, and MCF7 cells. These data suggest that
DHAs eﬀects on fortilin are not limited to U2OS cells.
Fig. 3. DHA shortens the half–life of fortilin protein. (A) Western-blot
analysis of fortilin and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) in cells treated with either 20 lM DHA or Vehicle
(DMSO). (B) Quantitative analyses of fortilin signals. Open circles:
fortilin expression indices of cells not treated by DHA. Closed circles:
fortilin expression indices of cells treated by DHA. Cells were pre-
treated with cyclohexamide and then with DMSO (vehicle) or 20 lM
DHA (A), followed by the calculation of fortilin expression indices,
fortilin signals normalized to corresponding GAPDH signals and
expressed as a percentage of the values at time zero (B).
Fig. 4. DHA-induced shortening of fortilins half-life is mediated by
proteasome pathway. (A) Western-blot analysis of fortilin and
GAPDH in cells treated with DMSO (DHA 0 lM), 20 lM DHA, or
20 lMDHA plus MG132. (B) Quantitative analyses of fortilin signals.
Closed triangles: fortilin expression indices of cells treated with both
DHA and MG132, open circle: DMSO (vehicle) only, closed circle:
DHA only. Cells were pre-treated with cyclohexamide and when
appropriate also with MG132 before they were treated with vehicle
(DMSO) or 20 lM DHA (A). Fortilin expression indices were
calculated by normalizing fortilin signals to corresponding GAPDH
signals and expressing them as a percentage of the values at time zero
(B).
Fig. 5. DHA increases fortilin ubiquitination. a-FLAG, anti-FLAG
antibody; a-GAPDH, anti-GAPDH antibody; Ub, ubiquitin. U2OS
cells were co-transfected with pcDNA-Ub and pFLAG-fortilin, treated
with DHA, harvested into SDS-loading buﬀer, and evaluated by
Western blot analysis. DHA dose-dependently increased the ubiqui-
tination of fortilin.
Fig. 6. DHA decreases the steady-state levels of fortilin protein and
increases the transcription of fortilin messages in U2OS cells. (A)
Western-blot analysis of fortilin and GAPDH in cells treated with
vehicle (DMSO, 0 lM DHA), 20 lM and 50 lM DHA. (B) Quanti-
tative analyses of fortilin signals. ANOVA showed that the concen-
tration of DHA had a signiﬁcant negative correlation with fortilin
expression index (P = 0.003, N = 2). Cells were treated with vehicle
(DMSO), 20 or 50 lM DHA for 48 h (A). Fortilin expression indices
were calculated by normalizing fortilin signals to corresponding
GAPDH signals and expressing them as a percentage of the values
at 0 lM DHA (B). (C) Real-time qRT-PCR of fortilin message in
U2OS cells treated with DHA. Fortilin message index: fg of fortilin
mRNA per ng of total RNA. ANOVA reveals that the concentration
of DHA had a signiﬁcant positive correlation with fortilin message
index (P = 0.02, N = 3).
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DHA-induced DNA fragmentation
Finally, we evaluated if and how DHA induces DNA frag-
mentation in U2OS cells. We ﬁrst generated U2OS-sh-fortilin,
U2OS cells with reduced fortilin expression via the sh-RNAagainst fortilin (see Section 2 for details) and U2OS-sh-empty,
their control cells. In addition, we had generated U2OS-forti-
lin, U2OS cells stably overexpressing fortilin, and U2OS-
Fig. 7. DHA decreases cellular fortilin levels in various cell types.
VSMC, vascular smooth muscle cells; A549 and H1299, lung cancer
cell lines; U2OS, osteosarcoma cell line; MDA468 and MCF7, breast
cancer cell lines. Cells were treated with vehicle (DMSO, DHA[]), 20
lM DHA (DHA[+]) for 48 h. Fortilin expression indices were
calculated by normalizing fortilin signals to corresponding GAPDH
signals.
Fig. 8. Cells lacking fortilin are less susceptible to DHA-induced DNA
fragmentation. (A) U2OS-sh-fortilin, U2OS cells that are stably
transfected with sh-RNA against fortilin and express a smaller amount
of fortilin; U2OS-sh-empty, U2OS cells stably transfected with empty
sh-RNA vector; NS, not statistically signiﬁcant; ***P < 0.005. The lack
of fortilin signiﬁcantly reduces the sensitivity of U2OS cells to DHA.
(B) U2OS-fortilin, U2OS cells stably overexpressing fortilin; U2OS-
empty, U2OS cells stably transfected with empty pcDNA vector; NS,
not statistically signiﬁcant; ***, P < 0.005; +, P = 0.085. The fortilin
overexpression increases the sensitivity of U2OS cells to DHA.
T. Fujita et al. / FEBS Letters 582 (2008) 1055–1060 1059empty, their control cells. We treated these cells with 20 lM
DHA and subjected them to DNA fragmentation assays.
DHA at 20 lM caused more apoptosis (DNA fragmentation)
in U2OS-sh-empty cells than in U2OS-sh-fortilin cells
(Fig. 8A), suggesting that the lack of fortilin decreased the sen-
sitivity of U2OS cells to DHA. Consistently, DHA caused
more apoptosis in U2OS-fortilin cells than in U2OS-empty
cells (Fig. 8B). These data suggest that the presence of fortilin
was required for DHA to exert its full apoptotic eﬀects and
that DHA kills cells—at least partly—through the targeting,
inactivation and elimination of fortilin (Fig. 9).4. Discussion
The signiﬁcance of the current work is that we established
the presence of binding of DHA (Fig. 1) to human fortilin
(Kd = 38 lM) and the biological signiﬁcance of the binding.
To our knowledge, the fact that DHA binds human fortilinFig. 9. The biological consequences of DHA-binding to fortilin - DHA is a
human fortilin. Fortilin bound by DHA is recognized as altered, ubiquitina
blocked by proteasome inhibitors such as MG132. While the sudden reducti
death or be more susceptible to other cytotoxic stimuli, cells chronically expr
cytotoxicity in both fortilin-dependent (red solid arrow) and -independent (rand decreases cellular fortilin levels has not been reported.
The Kd ﬁts well with the results of in vivo experiments where
20–50 lM DHA decreased cellular fortilin levels (Figs. 3, 4,
6 and 7).
The fact that DHA induce cytotoxicity and apoptosis in can-
cerous cells has been reported by several groups. Lai and oth-
ers treated molt-4 lymphoblastoid cells with 200 lMDHA and
showed their survival was less than 50% after 8 h incubation
[17]. Kim and others showed that a glioma cell line—
U373MG—is susceptible to DHA with IC50 of 70 lM [18].
Our current observation (Fig. 8) is consistent with above ﬁnd-
ings and add that the apoptosis by DHA of U2OS cells is atfortilin inhibitor. (), Negative feedback; Ub, ubiquitin. DHA binds
ted, and subjected to proteasome-mediated degradation, which can be
on by DHA of cellular fortilin levels causes cells to either undergo cell
ess lower levels of fortilin may be less sensitive to DHA. DHA induces
ed dotted arrow) fashions.
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knockdown (Fig. 8A) and overexpression (Fig. 8B) of fortilin
made U2OS cells less and more sensitive to DHA, respectively.
In other words, fortilin was required for DHA to exert its full
apoptotic eﬀects.
The fact that DHA induces apoptosis by targeting fortilin
does not exclude a possibility that DHA induces apoptosis
by activating other apoptosis pathways. In fact, DHAs bind-
ing to fortilin is moderate at best—DHA is only an imperfect
fortilin antagonist. To make the matter complex, the other
apoptosis pathways activated by DHA can directly or indi-
rectly be antagonized by fortilin, an anti-apoptotic molecule.
It is also possible that DHA-bound fortilin may become pro-
apoptotic. Further investigation is called for to identify and
characterize the pathways by which DHA induces apoptosis
without directly attacking fortilin.
It is shown here that DHA is a viable lead compound to de-
velop more speciﬁc fortilin inhibitors and that human fortilin
is a critical target of DHA and its derivatives. Such fortilin
inhibitors would negate the biological function of fortilin sim-
ply by facilitating the degradation of fortilin in cells (Fig. 9).
Since fortilin is required to sustain the life of many cancerous
cells [1,2,15,19], such fortilin inhibitors would cause cells to go
into severe fortilin deﬁciency and cell death and prove to be
potent anti-cancer drugs in fortilin-overexpressing cancers.
Encouragingly, DHA and its derivatives are extremely well-
tolerated medication, with reported median lethal doses in
mice being 4228 mg/kg [5], suggesting that derivatives of
DHA would also be well tolerated by patients. That said, fur-
ther biological analyses using whole organisms will be required
to deﬁnitively determine the eﬃcacy of the fortilin-targeting
strategies in cancer chemotherapies. In the initial screening
of such DHA derivatives, SPR (Fig. 2) and fortilin-knock-
down cell (Fig. 8) systems described in the current work will
prove to be invaluable tools.
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